key: cord-0940968-cz8imf4s
authors: Zhou, Dongyan; Fuk-Woo Chan, Jasper; Zhou, Biao; Zhou, Runhong; Li, Shuang; Shan, Sisi; Liu, Li; Zhang, Anna Jinxia; Chen, Serena J.; Chung-Sing Chan, Chris; Xu, Haoran; Kwok-Man Poon, Vincent; Yuan, Shuofeng; Li, Cun; Ka-Heng Chik, Kenn; Chun-Yiu Chan, Chris; Cao, Jianli; Chan, Chun-Yin; Kwan, Ka-Yi; Du, Zhenglong; Tsz-Kan Lau, Thomas; Zhang, Qi; Zhou, Jie; Kai-Wang To, Kelvin; Zhang, Linqi; Ho, David D.; Yuen, Kwok-Yung; Chen, Zhiwei
title: Robust SARS-CoV-2 Infection in Nasal Turbinates after Treatment with Systemic Neutralizing Antibodies
date: 2021-02-25
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.02.019
sha: 310a593464c1e00c0f9206d6c7f04f86cf68cf8e
doc_id: 940968
cord_uid: cz8imf4s

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC50 range, 0.0007-0.35 μg/ml) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1-3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection and vaccine.

has been reported to be beneficial in the treatment of severe COVID-19 in small case cohorts 88 . To replace convalescent plasma, which is not readily available in most 89 J o u r n a l P r e -p r o o f et al., 2020b). Twenty-four hours after the ZDY20 injection, each animal was challenged 187 intranasally with 10 5 plaque-forming units (PFU) of live SARS-CoV-2 (HKU-001a strain) 188 (Chan et al., 2020a; Liu et al., 2020b) . At 4 dpi, nasal turbinate, trachea and lung tissues were 189 harvested to quantify infectious viruses by plaque assay, viral loads by real-time reverse-190 transcription polymerase chain reaction (RT-PCR) and infected cells by immunofluorescence 191 staining (IF). We found that infectious PFUs were readily detected in all tissue compartments 192

of VRC01-controlled hamsters tested but not in 75% and 0% nasal turbinates, 75% and 67% 193 trachea, and 50% and 33% lungs of hamsters that were given high and low doses of ZDY20, 194 respectively ( Figure 3B ). The more sensitive RT-PCR further demonstrated that viral RNA 195 copy numbers were reduced in the lungs by an average of 3 logs (range, 0.7-4.5) ( Figure 3C ) . 196 In contrast, there was no significant viral load reduction in nasal turbinates and trachea in 197 both dose groups, suggesting less preventive efficacy by ZDY20 in the URT of viral entry. 198

To determine the role of ZDY20 in protection, we measured the serum antibody 199 concentration and neutralization titer at 0 dpi and 4 dpi. Over 40 µg/ml and 9 µg/ml ZDY20 200 were found in 50% high-dose and 67% low-dose animals at 0 dpi ( Figure 3D , solid symbol 201 and Table S5 ), together with mean IC 50 values of approximately 1:236 and 1:99, respectively 202 ( Figure 3E , solid symbol). On 4 dpi, over 26 µg/ml and 5 µg/ml ZDY20 were found in 50% 203 high-dose and 67% low-dose animals ( Figure 3D , open symbol and Table S5) These results demonstrated that most animals maintained peripheral amounts of ZDY20 206 much higher than its IC 90 values during the entire course of the experiment. 207

Next, to understand whether or not ZDY20 protects against infection-induced lung injury in 208 hamsters, we performed pathological analysis on lung specimens. Compared with uninfected 209 healthy animals ( Figure S4 ), hamsters treated with the high-dose ZDY20 showed mild 210 interstitial alveoli inflammation with minor septal infiltration and congestion ( Figure 3F Figure S4 ). In the high-dose group, little viral NP 220 expression was observed in lung sections ( Figure 3F , top right). In the low-dose group, a 221 small amount of viral NP was observed in localized areas of alveoli ( Figure 3F , middle right, 222 arrows) and in the epithelia of a few bronchiolar sections (thin arrows). In contrast, control 223 hamsters showed diffuse NP expression in extensive areas of alveoli ( Figure 3F , bottom right, 224 thick arrows) and in the bronchiolar epithelia (thin arrows). The mean number of NP + cells 225 per 50× field in the lungs was significantly lower in the high-dose group than that in the 226 control animals ( Figure 3G ). Remarkably, nasal turbinate tissues showed damage to the 227 respiratory and olfactory epithelium with extensive submucosal immune cell infiltration, 228 together with robust and diffuse viral NP expression in extensive areas lining the stratified 229 squamous epithelia in both the high-dose and low-dose groups of ZDY20-treated animals, 230 similar to untreated control hamsters ( Figure 4A -C). Moreover, no significant difference in 231 NP + cells per 50× field was found between treated and control animals when nasal turbinate 232 tissues were analyzed ( Figure 4D ). Collectively, these results demonstrated that prior 233 administration of 10 mg/kg ZDY20 did not prevent robust SARS-CoV-2 infection in nasal 234 turbinates but suppressed productive infection in lungs in the Syrian hamster model. 235

Considering that HuNAbs with greater inhibitory potency may be more effective in 236 preventing viral replication in the nasal turbinates, we tested two such RBD-specific HuNAbs 237 namely ZB8 and 2-15. ZB8 is a newly cloned HuNAb with IC 50 and IC 90 values of 0.013 and 238 0.031 µg/ml whereas 2-15 has been previously reported with IC 50 and IC 90 values of 0.0007 239 and 0.04 µg/ml all in the live virus neutralization assay (Table S6) (Liu et al., 2020b) . ZB8 240 and 2-15, therefore, are up to 32-fold (IC 90 ) to 500-fold (IC 50 ) stronger than ZDY20. 241

Prophylactic intraperitoneal injection of 4.5 mg/kg ZB8 and 1.5 mg/kg 2-15 were tested in 242 hamsters using the same protocol as ZDY20. We consistently observed significantly reduced 243 viral loads and NP + cells in the lungs but not in nasal turbinates of experimental hamsters on 244 4 dpi in both experiments ( Figure 5A -5B and Figures S5 and S6) . We subsequently tested 245 prophylactic intranasal inoculation of 10 mg/kg ZDY20 and 4.5 mg/kg ZB8, respectively, 246 followed by the same viral challenge at 12 hours post the antibody intervention ( Figure 5C  247 and Figure S7) . Surprisingly, we observed significantly reduced infectious PFUs and viral 248 loads in lungs mainly by ZB8 but still not in nasal turbinates of experimental hamsters on 4 249 dpi in both experiments. Abundant NP + cells were readily found in nasal turbinate of each 250 treated animal. In addition, we examined the efficacy of a systemic DNA vaccine that was 251 codon-optimized and encoded the full-spike protein as we previously described for SARS (Yi 252 Postchallenge ZDY20 Therapy Reduces SARS-CoV-2 Infection in the Lungs but 264

To explore the therapeutic potential of ZDY20, we infected four groups of hamsters (n = 4 266 per group) as described above. Three groups of hamsters were then treated intraperitoneally 267 with a single high dose of 10 mg/kg at 1, 2 and 3 dpi ( Figure 6A , color-coded). The fourth 268 group was the VRC01 control using the same dose at 1 dpi. All animals were consistently 269 sacrificed at 4 dpi for measurements of infectious virus titers and viral RNA copy numbers in 270 lung, trachea and nasal turbinate tissues ( Figure 6B and 6C). At 1 dpi, ZDY20-treated 271 hamsters showed no measurable infectious viruses in 100% nasal turbinates, 100% trachea 272 and 75% lungs by the plaque assay ( Figure 6B , blue). The mean viral load reduction was 0.7 273 logs in both nasal turbinates (range, 0.1-1.0 logs) (p<0.05) and trachea (range, 0.3-1.5 logs) 274 but was 1.2 logs (range, 0.8-1.8 logs) in lungs (p<0.01) compared with the control group 275 ( Figure 6C , blue). At 2 dpi, ZDY20-treated hamsters presented no measurable infectious 276 viruses in 75% nasal turbinates, 75% trachea and 50% lungs ( Figure 6B , red). The mean viral 277 load reduction was 1 log (range, 0.3-1.5 logs) in the trachea (p<0.05) but not significant in 278 the nasal turbinates and lungs compared with the control group ( Figure 6C , red). At 3 dpi, 279 ZDY20-treated hamsters had no measurable infectious viruses in 25% nasal turbinates, 75% 280 trachea and 25% lungs ( Figure 6B , green). The mean viral load reduction was not significant 281 in the nasal turbinates, trachea or lungs compared with the control group ( Figure 6C, green) . 282

These kinetics results demonstrated that earlier commencement of treatment within 2 dpi 283 resulted in a more significant reduction of infectious viruses. For more significant viral load 284 reduction, commencement of treatment within 1 dpi is likely necessary. To determine the role 285 of ZDY20 in protection, we measured the antibody concentration and neutralization titer at 4 286 dpi. Over 40 µg/ml ZDY20 was found in 100% treated animals at 1 dpi, 75% treated animals 287 at 2 dpi and 50% treated animals at 3 dpi ( Figure 6D and Table S5 ), together with mean IC 50 288 values of 1:169, 1:62 and 1:69 in each corresponding group ( Figure 6E ), respectively. 289

Subsequently, we performed pathological analysis on lung specimens to understand whether 290 ZDY20 protects against tissue injury in hamsters. The H&E-stained sections of control 291 hamsters showed acute lung injury with peribronchiolar infiltration, bronchiolar epithelial 292 cell death, diffuse alveolar wall thickening, patchy areas of alveolar space infiltration, 293 exudation and vasculitis ( Figure 6F , top). In contrast, less severe histopathological changes 294 were observed in all 3 groups of ZDY20-treated hamsters. There was no apparent 295 peribronchiolar infiltration in hamsters treated at 1 dpi. The bronchiolar epithelia appeared 296 normal, with only occasionally observed cell death in hamsters treated at 2 dpi. Moderate 297 alveolar wall thickening and capillary congestion without alveolar space infiltration or 298 exudation and limited vasculitis were observed in hamsters treated at 3 dpi. Corroboratively, 299 abundant SARS-CoV-2 NP expression in the bronchiolar epithelium and alveoli was 300 observed in the lungs of control hamsters ( Figure 6F , bottom). In ZDY20-treated hamsters, 301 NP expression was confined to small areas of alveoli at 1 dpi and was more frequently found 302 in the bronchiolar epithelia at 2 dpi and 3 dpi. The mean number of NP + cells per 50× field of 303 lung tissues at 1 dpi was significantly lower than that of the control group ( Figure 6G ). 304 Importantly, when we performed IF staining of viral NP antigen in nasal turbinate tissues, 305 robust and diffuse viral NP expression in extensive areas lining the stratified squamous 306 epithelia was found in infected hamsters treated with 10 mg/kg ZDY20 either at 1 dpi, 2 dpi 307 or 3 dpi, similar to untreated control hamsters ( Figure 7A ). These results demonstrated that 308 postchallenge treatment with 10 mg/kg ZDY20 suppressed robust SARS-CoV-2 infection in 309 the lungs but not in the nasal turbinates in the hamster model ( Figure 7B To further understand the difficulty of sterile protection in the URT, we sought to measure 313 the amounts of i.p. injected HuNAb in nasal wash and tissue homogenates. In contrast to 314 high amounts of ZDY20, ZB8 and 2-15 detected in animal sera (Tables S5 and S6) , no 315 measurable amounts of antibodies were found in nasal wash specimens of hamsters tested. 316

Various amounts of antibodies, however, were found in nasal turbinate and lung 317 homogenates ( Figure S9 ). When we included all hamsters from both ZDY20 prevention and 318 treatment experiments, together with 2-15 prevention ( Figure S6 ) and intranasal prevention 319 of ZDY20 and ZB8 ( Figure S7 ) for analysis, the amount of peripheral HuNAb was negatively 320 correlated with NP + cells in the lungs but not in the nasal turbinates ( Figure 7C ). Furthermore, 321 there was a significant negative correlation between the tissue HuNAb concentration and the 322 number of infectious viral PFU either in nasal turbinate or in lung homogenates (except that 323 nasal turbinates of 5 animals in the 2-15 prevention experiment were not available for 324 measuring PFU) ( Figure 7D ). Therefore, HuNAb in tissue homogenates might account for 325 the significant reduction of infectious viral particles in both nasal turbinates and lungs once 326 the antibody encounters the virus for neutralization during the PFU measurement experiment. in homogenized nasal turbinate tissues. We reasoned that the reduction was likely due to 370 blood-derived potent HuNAb during tissue homogenization for the in vitro assay. Indeed, low 371 amounts of ZDY20 and ZB8 were detected in homogenized nasal turbinate tissues. Moreover, 372 the amount of HuNAb was negatively corelated with the PFU number of infectious viruses in 373 both lung and nasal turbinate homogenates, suggesting that SARS-CoV-2 could be 374 neutralized when it encountered the sufficient amount of neutralizing antibody. Since the 375 amounts of ZDY20 and ZB8 were very low in nasal wash, our results suggested that the 376 insufficient passive immunization for sterile protection is probably due to poor distribution of In our postchallenge treatment kinetics study, we showed that early use of ZDY20, preferably 400 within 2 dpi, suppressed infectious virus, viral loads and acute injury in the lungs of treated 401 hamsters. In nasal turbinates, however, robust viral loads and NP + cells were readily observed 402 for treatment even at 1 dpi, except for the reduced numbers of infectious viruses in 403 homogenized tissues. Since the amount of peripheral ZDY20 was negatively correlated with 404 NP + cells in the lungs but not in the nasal turbinates, the therapeutic efficacy of injected 405 another study, after a 25 mg/kg dose of a noncompeting pair of HuNAbs given at 12 hpi, viral 411 loads were reduced for over 2 logs, yet there were still 10 6 copies/g of lung tissues at 3 days 412 after virus challenge in hACE2-transgenic mice (Wu et al., 2020b) . In monkey models, a 413 preprint article indicated that SARS-CoV-2 viral loads were detected in nasopharyngeal 414 swabs at 4 dpi in animals that received a very high dose of 150 mg/kg of the REGN-COV2 415 antibody cocktail at 1 dpi (Baum et al., 2020) . Moreover, an intraperitoneal dose of 50 416 mg/kg treatment with the RBD-specific CB6 antibody that has an IC 90 value of 1 µg/ml 417 reduced but did not completely prevent histopathological changes in the lungs of SARS-418

CoV-2-infected monkeys . In addition to these HuNAb studies, for 419 convalescent plasma therapy, we previously reported that convalescent sera of infected 420 hamsters reduced SARS-CoV-2 replication but not acute lung injury (Chan et al., 2020a) . See also Table S5, Figure S4 and Figure S9 . See also Table S5, Figure S4 and Figure S9 . See also Table S5 -S6, Figure S4 , Figure S6 , Figure S7 and Figure S9 . 

Lead Contact 649

Further information and requests for resources and reagents should be directed to and will be 650 fulfilled by the Lead Contact, Zhiwei Chen (zchenai@hku.hk). 651 652

Materials Availability 653

This study did not generate new unique reagents. 654 655

Data and Code Availability 656

The study did not generate any unique datasets or codes. Scientific) and were incubated in a 37℃ incubator with ≥80% relative humidity and 5% CO2 684 setting on an orbital shaker platform at 125±5 rpm (New Brunswick innova TM 2100) 685 according to the manufacturer's instructions. 686

Total RNA was extracted from peripheral blood lymphocytes of convalescent SARS-CoV2 689 patients by RNeasy Mini kit (Qiagen), and both total RNA and mRNA were reverse 690 transcribed into cDNA using PrimeScript 1st strand cDNA Synthesis Kit (Takara). Fd 691 segment (variable and first constant domain of the heavy chain) genes and light-chain genes 692 were amplified by using primers (Table S7 ) specific for the human chain genes (Michael 693 Hust, 2012) . Then, the amplified chains were assembled into the pComb3X phage display 694 vector using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England BioLabs, 695 NEB). The assembled products were transformed into Escherichia coli TG1 (Lucigen) and 696 resulted in a library of 3×10 6 clones. The transformants were expanded into a volume of 2 697 liters, and the resulting phage was recovered as described previously (Michael Hust, 2012) . 698

This panning procedure was adapted from previously described procedures (Chames, 2012) . antibody (1:4000 dilution with 1% BSA/PBS) was incubated at 4°C overnight. This step was 871 followed by FITC-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch) for 30 min 872 and then mounted with 4',6-diamidino-2-phenylindole (DAPI). All tissue sections were 873 examined, and the images were captured with an Olympus BX53 semimotorized fluorescence 874 microscope using cellSens imaging software (Olympus). NP + cells per 50× magnification 875 field were quantified based on the mean fluorescence intensity (MFI) using the ImageJ 876 (https://imagej.nih.gov/ij/ download.html). 877

Statistical analysis was performed using PRISM 6.0 or SPSS 26.0. Ordinary one-way 879 ANOVA and multiple comparisons were used to compare group means and differences 880 between multiple groups. Unpaired t test was used to compare group means between two 881 groups only. A P-value < 0.05 was considered to be significant. 

REGN-COV2 antibodies prevent and treat SARS-888

CoV-2 infection in rhesus macaques and hamsters

A Randomized Trial of 891 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-894

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Phage display and selections on purified antigens

Simulation of the clinical and 900 pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian 901 hamster model: implications for disease pathogenesis and transmissibility

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a 905 patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect

Improved Molecular Diagnosis of COVID-19 by the 908 Novel, Highly Sensitive and Specific COVID-19

Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

A familial cluster of pneumonia associated with the 2019 novel 913 coronavirus indicating person-to-person transmission: a study of a family cluster

Isolating and engineering human antibodies using yeast surface display

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in 920 Outpatients with Covid-19

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of 923 severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies 924 primarily targeting the receptor binding region

A neutralizing human antibody binds to the N-terminal domain of the 927 Spike protein of SARS-CoV-2

Comparative tropism, replication kinetics, and cell 930 damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical 931 manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Commentary: Could iron 934 chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Remdesivir for 5 or 10 Days in 941 Patients with Severe Covid-19

Simian immunodeficiency virus infection evades vaccine-elicited antibody 944 responses to V2 region

SARS-CoV-2 Reverse Genetics 947 Reveals a Variable Infection Gradient in the Respiratory Tract

SARS-CoV-2 shedding and seroconversion among 950 passengers quarantined after disembarking a cruise ship: a case series

Triple combination of interferon beta-1b, lopinavir-ritonavir, 954 and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, 955 randomised, phase 2 trial

SARS-CoV-2 proteome microarray for global profiling of COVID-19 958 specific IgG and IgM responses

Effect of Convalescent 961 Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month 962 Experience

SARS-CoV-2 vaccines in development

Structure of the SARS-CoV-2 spike receptor-binding domain bound to 966 the ACE2 receptor

High neutralizing antibody titer in 969 intensive care unit patients with COVID-19

Potent neutralizing antibodies against multiple epitopes on 972 SARS-CoV-2 spike

Anti-spike IgG causes severe acute lung injury by skewing macrophage 975 responses during acute SARS-CoV infection

Dynamic 977 surveillance of SARS-CoV-2 shedding and neutralizing antibody in children

Construction of human naive antibody gene libraries

Clinical progression and viral load in a community 985 outbreak of coronavirus-associated SARS pneumonia: a prospective study

CoV-2 antiviral drugs through large-scale compound repurposing

Convergent antibody responses to 992 SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies 995 and protection from disease in a small animal model

Interim Results of a Phase 1-2a 998 Trial of Ad26.COV2.S Covid-19 Vaccine

COVID-19 vaccine BNT162b1 elicits 1001 human antibody and TH1 T cell responses

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Potent neutralization of SARS-CoV-2 1007 by human antibody heavy-chain variable domains isolated from a large library with a new 1008 stable scaffold

Rapid 1011 Generation of Neutralizing Antibody Responses in COVID-19 Patients

Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv

COVID-19 re-infection by a phylogenetically distinct 1018 SARS-coronavirus-2 strain confirmed by whole genome sequencing

Temporal profiles of viral load in posterior 1022 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-1023 2: an observational cohort study

Safety and efficacy of the 1026 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 1027 randomised controlled trials in Brazil, South Africa, and the UK

Receptor recognition by novel 1029 coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

SARS-CoV-2 neutralizing antibody responses are more robust 1033 in patients with severe disease

Kinetics of viral load and antibody response in relation to 1036 COVID-19 severity

Identification of Human Single-Domain Antibodies against SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus 1042 binding to its receptor ACE2

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety 1045 and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Single amino acid substitutions in 1048 the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry 1049 and immunogenicity of a major neutralizing domain

Structural basis of a shared antibody response to SARS-CoV-2. 1052 Science

Acute SARS-CoV-2 infection impairs dendritic cell and T cell 1055 responses

A Novel Coronavirus from Patients with Pneumonia in China

Potently neutralizing and protective human 1061 antibodies against SARS-CoV-2

Comprehensive analysis of pathogen-specific antibody response in vivo based on 1064 an antigen library displayed on surface of yeast

washes were performed to narrow down the diversity and enrich for only specific, stronger 714 binders from the phage library. Polyclonal phage ELISA was carried out at Round 2, and if 715 phages were not sufficiently enriched at this stage, then a third round was carried out. All 716 panning procedures were performed in solution using low protein binding 1.5 ml Eppendorf 717 tubes. 718

The procedures of phage ELISA were adapted from previously described procedures 720 (Chames, 2012 for ELISA as the polyclonal phage ELISA with a 1:1 dilution with 4% skimmed milk in PBS. 733The strong single binders were sent for sequencing. For recombinant protein ELISA, the 734 RBD or spike proteins were coated on 96-well enzyme-linked immunosorbent assay plates at 735 50 ng/well. After blocking with 4% skimmed milk in PBS, 50 μl of HuNAbs was added to 736 the plates at 1:5 serial dilutions starting from 10 µg/ml and then incubated for 1 h at 37°C. 737The plates were washed, and the secondary antibody anti-human IgG-HRP (Invitrogen) was 738 added. 3,3′,5,5′-Tetramethylbenzidine liquid substrate (Sigma-Aldrich) was used for color 739 development. Optical density at 450 nm was read on a Varioskan LUX multimode microplate 740 reader (Thermo Fisher Scientific). 741

The antibody VH/VL and constant region genes were amplified and cloned into the 743 expression vectors AbvecIgG and AbvecIgKappa using the NEBuilder® HiFi DNA 744Assembly Cloning Kit (NEB). The plasmids of paired IgH and IgL genes were cotransfected 745 into the Expi293F expression system (Thermo Fisher Scientific) following the 746 manufacturer's protocol to produce recombinant HuNAbs. Antibodies from cell culture 747 supernatants were purified immediately by affinity chromatography using Recombinant 748Protein G Agarose (Thermo Fisher Scientific) according to the manufacturer's instructions. 749The purified HuNAbs were concentrated by an Amicon ultracentrifuge filter device 750 (molecular weight cutoff, 50 kDa; Millipore) to a volume of 0.2 ml in PBS and stored at -751 80°C. To produce Fab fragments, antibodies were cleaved using Protease Lys-C (Roche) with 752 an IgG to Lys-C ratio of 4000:1 (w/w) in 10mM EDTA, 100mM Tris-HCl, pH 8.5 at 37 °C 753 for approximately 12h. Fc fragments were removed using Protein A Sepharose (GeneScript). 754

The neutralizing activity of NAbs was determined using a pseudotype-based neutralization 756 assay as we previously described (Liu et 

The SARS-CoV-2 focus reduction neutralization test (FRNT) was performed in a certified 769 biosafety level 3 laboratory. Neutralization assays against live SARS-CoV-2 were conducted 770 using a clinical isolate (HKU-001a strain, GenBank accession no: MT230904.1) previously 771 obtained from a nasopharyngeal swab of an infected patient (Chu et al., 2020